A-osakkeiden muuntaminen B-osakkeiksi

Yhtiöjärjestyksen 3 §:n nojalla 47.000 A-osaketta on muunnettu 47.000 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 17.8.2000. Muuntamisen jälkeen yhtiön osakkeista on A-osakkeita 34.518.547 kpl ja B-osakkeita 32.999.874 kpl.

ORION-YHTYMÄ OYJ

Henry Haarla Brita Kivimäki

Recommended Reading

August 10, 2026 07:05 ET | Source: Orion Oyj

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary...
Read More

$Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint$
July 17, 2026 05:00 ET | Source: Orion Oyj

Orion Group Half-Year Financial Report January–June 2026

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6...
Read More